Business Wire

ATRC

12.2.2024 15:12:30 CET | Business Wire | Press release

Share
UAE's ATRC Launches Global Tech R&D Platform at WGS 2024: Allocates US$200 Mn Fund to Accelerate Innovation for Developing Nations

In a landmark announcement on Day 1 of the World Governments Summit (WGS) 2024, Abu Dhabi’s Advanced Technology Research Council (ATRC) unveiled a pioneering initiative aimed at facilitating global access to cutting-edge technology solutions. The newly launched ‘ATRC Global Tech R&D Platform’ serves as a channel for countries worldwide to tap into the UAE's technological expertise to address their unique challenges.

As the driving force behind Abu Dhabi and the wider UAE's advanced research and development (R&D) ecosystem, this initiative underscores ATRC's commitment to fostering inclusive growth and global prosperity. In an era of rapid technological transformation, the platform seeks to bridge technology gaps experienced by nations worldwide by offering tailored solutions to their pressing needs.

To initiate applications through the platform, ATRC is allocating US$200 million in funding to accelerate innovation, particularly for emerging and developing nations. By committing to absorb resource and research costs, the funding facilitates the development of sophisticated technology solutions, empowering these nations to keep pace with the latest advancements.

The ATRC Global Tech R&D Platform invites applications from governments, organizations, and eligible stakeholders all over the world, prioritizing collaboration, and inclusivity. Through a rigorous evaluation process, initiatives aligned with the platform's mission will receive support in six priority sectors: Aerospace and Space; Food and Agriculture; Healthcare; Safety and Security; Sustainability, Environment, and Energy; and Transport.

H.E. Faisal Al Bannai, Secretary General of ATRC, underscores the profound global impact of the initiative, stating: "Our commitment is to empower every nation with the means to thrive in this technology-driven world. ATRC stands ready to partner with countries worldwide, leveraging our expertise in technology to address their challenges and drive collective progress in the AI-driven era."

Over the span of almost four years, ATRC has developed a robust R&D ecosystem, with over 850 researchers from more than 70 countries. It has built an entire ecosystem that systematically supports every critical stage of a technology’s development journey. Its entity ASPIRE crowdsources global talent through grand challenges and global competitions and identifies technology gaps with its clients. The Technology Innovation Institute (TII) is focused on applied research with intentional outcomes and houses its leading researchers and scientists, while VentureOne commercializes its solutions, taking R&D products and services from lab to market.

ATRC offers a spectrum of capabilities spanning quantum and AI, autonomous robotics, and cryptography, as well as advanced materials, propulsion, and space – guiding technology needs from ideation to innovation.

From identifying an entity’s tech pain point to developing bespoke R&D solutions, ATRC orchestrates the complete lifecycle of technology advancement for companies and countries that need support. Situated at the global crossroads, it extends its reach to entities worldwide, facilitating innovation on a truly global scale.

Al Bannai is set to address a plenary session at the World Governments Summit, highlighting his views on AI’s evolution and emerging opportunities.

Dr. Ray O. Johnson, CEO of ATRC’s global applied research arm, TII, expressed optimism about the fund's potential to catalyze innovation, and said: "Through this platform, we will help identify untapped innovation around the world, unleashing the power of transformative technologies, and sparking economic growth."

ATRC is calling on nations to collaborate and contribute to the global technological landscape. For further details on the ATRC Tech R&D Fund, applicants can contact the Council via ASPIRE, at aspireuae.ae.

“We’re here to identify technology gaps and facilitate sophisticated solutions that countries may need to explore for a resilient future”, said Stephane Timpano, CEO of ASPIRE.

In a similar stance to support the wider adoption of advanced technologies, last year, the Technology Innovation Institute (TII) was among the first to open-source its world ranking large language model, Falcon 40B under the Apache 2.0 license – royalty-free.

*Source: AETOSWire

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240212472252/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press release

- frontMIND study evaluating tafasitamab (Monjuvi®/Minjuvi®) in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) selected for the prestigious Plenary Abstracts Session at EHA 2026 - Results showed tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) significantly prolonged progression-free survival (PFS), reducing risk of disease progression or death by 25% - Positive trends toward PFS benefit with Tafa-Len-R-CHOP were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypes - The frontMIND data support global regulatory applications for tafasitamab and lenalidomide in addition to R-CHOP for previously untreated DLBCL and HGBL Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified c

Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202612.6.2026 23:31:00 CEST | Press release

Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til

IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 18:36:00 CEST | Press release

Venneman brings more than 30 years of digital transformation, AI, and enterprise technology experience as IQM prepares for its planned Nasdaq listing IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, s

DEWA Organises Second Agentic AI Retreat at Al Shera’a, World’s Tallest, Largest and Smartest Net‑Positive Government Building12.6.2026 17:08:00 CEST | Press release

HE Saeed Mohammed Al Tayer, MD & CEO of Dubai Electricity and Water Authority (DEWA),has emphasised that DEWA deploys the latest Agentic AI technologies, in line with the vision to enhance its leading role and reinforce Dubai’s position as the city of the future. He made these remarks during the Agentic AI Executive Retreat DEWA organised at Al Shera’a, its new headquarters, which is the world’s tallest, largest and smartest net-positive government building. The event was attended by the executive leadership team and key stakeholders in digital transformation and artificial intelligence (AI), as well as representatives from SAP and McKinsey. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612633834/en/ DEWA organises second Agentic AI Retreat at Al Shera’a, world’s tallest, largest and smartest net positive government building (Photo: AETOSWire) In his speech, Al Tayer said that DEWA is guided by directives from the wise l

BeOne Medicines’ Foundational Hematology Franchise Leads Next Era of B-Cell Cancer Innovation at EHA 202612.6.2026 12:00:00 CEST | Press release

Tacabrutideg (BGB-16673, BTK degrader) showed durable responses in heavily pretreated R/R CLL and BTK inhibitor–naïve patients, signaling potential for earlier lines of treatmentBRUKINSA plus sonrotoclax (ZS) delivered deep, durable responses and high uMRD rates across TN CLL and R/R MCL and CLL, reinforcing its potential as an all-oral, fixed-duration treatment BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from its foundational hematology franchise at the 2026 European Hematology Association (EHA) Congress in Stockholm. Updated results from tacabrutideg (BGB-16673), a potential best-in-class Bruton’s tyrosine kinase (BTK) degrader, demonstrated durable responses in pretreated relapsed/refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), with early activity also seen in BTK inhibitor–naïve patients. These data are complemented by results from the all-oral combination of BRUKINSA® (zanubru

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye